Navigation Links
Pharsight to Present at DIA Cardiac Safety Conference on December 4, 2007
Date:11/28/2007

Dr. Timothy Carrothers Will Present Case Example on the Value of Modeling

and Simulation to Assess Potential for QTc Prolongation

MOUNTAIN VIEW, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Timothy Carrothers, Sc.D., senior scientist, Strategic Consulting Services, has been invited to speak to members of the pharmaceutical and biotechnology industries attending the 2nd Annual Drug Information Association (DIA) Cardiac Safety Conference, to be held in Prague, Czech Republic at the Dorint Praha Don Giovanni Hotel from December 3-4, 2007.

Dr. Carrothers will present a case study on the value of model-based approaches to assess drug effects on QTc prolongation and develop future clinical studies required for new drug approval. Dr. Carrothers' presentation, "Concordance Between the Exposure-QTc Response Relationship in the Pooled Phase 1 Data vs. Thorough QTc Study", is part of a dedicated conference session led by pharmaceutical sponsors and regulators on modeling the relationship between plasma concentration of a drug and its effect on QTc prolongation as an indicator of cardiac arrhythmic risk. The session speakers will present applied research on concentration-QTc modeling and discuss perspectives for its contribution to decisions on the development, regulatory approval and labeling of new drugs. A panel discussion will also provide a forum for scientific discussion and collaborative exchange on exposure-QTc response modeling. Additional information can be found at http://www.diahome.org.

"Model-based approaches provide important tools in the analysis and reporting of QT data, which is now required by the FDA for all new drug submissions to support more informed decision-making," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "These predictive approaches integrate data across a variety of studies, allowing assessment of drug effects on QTc based on the totality of the underlying clinical data, and support trial design of QTc studies. Our scientists' collective experience with modeling QTc prolongation as an important and intensively studied measure of cardiac safety risk spans multiple indications and drug classes. Pharsight is pleased to be invited to the DIA Safety Conference, to share its perspectives on QTc modeling with industry colleagues and to exchange information on emerging trends in cardiac safety and risk assessment."

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trade marks of their respective companies or organizations.


'/>"/>
SOURCE Pharsight Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Pharsight Files Application for Nasdaq Capital Market Listing
2. Pharsight to Host European Software Conference
3. Pharsight Expands Global Consulting Services Teams
4. Pharsight Achieves $7.3 Million in Quarterly Revenue
5. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
6. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
7. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
8. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
9. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
10. AtriCure to Present at Roth Capital Partners 2007 New York Conference
11. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... , ... April 25, 2017 , ... ... a modern procedure that achieves results in a fraction of the time as ... Vegas, NV, with Significance Dental Specialists, now offers this revolutionary treatment with or ...
(Date:4/25/2017)... RESTON, VIRGINIA (PRWEB) , ... April 25, 2017 ... ... scientists leading the way in unveiling cutting-edge birth defects research related to Zika ... recognized by the world’s premier society for this important science. , ...
(Date:4/25/2017)... ... 2017 , ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace ... help but be heartened by the industry’s current surge. But another thing that unifies ... smell.” At last they can simply, safely and effectively end their aroma anguish ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... addition of predictive analytics to its patient care management module. Using this new ... before a patient has been initiated on continuous positive airway pressure (CPAP), oral, ...
(Date:4/25/2017)... ... April 25, 2017 , ... There is no better place in South Florida ... report in the May issue of Consumer Reports focused on heart health. , ... achieved during and after coronary bypass and aortic valve replacement procedures. , Consumer ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... WOONSOCKET, R.I. , April 20, 2017 /PRNewswire/ ... (NYSE: CVS), today unveiled a new store design ... new assortment of healthier food, health-focused products and ... the store to help customers discover new offerings. ... represent the next evolution of the customer experience ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, ... ... at US$ 7,167.6 Mn in 2015, and is expected to ... of 5.6% from 2016 to 2024. The ...
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, Chile, ... their offering. ... Latin American pharmaceutical contract manufacturing services market is anticipated to ... registration cost in Latin American countries and continuous economic growth ...
Breaking Medicine Technology: